ECNS Stock: iShares MSCI China Small-Cap ETF VanEck Profile & Analysis (2026)
A targeted investment vehicle providing exposure to the smallest 14% of the Chinese equity market across various sectors. — Updated May 2026 with current AUM, expense ratio, holdings, and performance data.
The iShares MSCI China Small-Cap ETF VanEck (ECNS) offers investors a unique gateway into the most dynamic segment of the Chinese economy: its small- and micro-cap enterprises. While many broad-market funds are dominated by massive state-owned enterprises or tech giants, ECNS tracks the MSCI China Small Cap Index, capturing the bottom 14% of the market. This includes a diverse array of companies listed as H-shares and Red Chips on the Hong Kong Stock Exchange, as well as firms in the emerging tech and healthcare sectors. For investors who track niche growth areas, comparing these firms against a list of small cap aerospace & defense stocks can highlight the distinct risk-reward profile of Chinese industrial growth.
With a significant 19% allocation to Health Technology, ECNS is a major player for those interested in international medical innovation. This heavy weighting makes it a relevant companion for those already monitoring the complete list of biotechnology companies listed on U.S. exchanges. As of May 2026, the fund has demonstrated impressive momentum with a year-to-date return exceeding 36%, signaling a robust recovery for domestic-focused Chinese businesses after several years of volatility.
Key Takeaways — ECNS Stock
Unlike major Chinese ETFs, ECNS exclusively targets the bottom 14% of market capitalization, avoiding the heavy influence of mega-cap tech and state banks.
With a yield of 5.63%, ECNS provides a substantial income stream that is rare for international small-cap growth funds.
The fund maintains a nearly 20% allocation to Health Technology, offering concentrated exposure to China’s rapidly evolving medical and biotech landscape.
Performance has surged with a 36.42% YTD return, reflecting a sharp pivot in sentiment toward Chinese domestic growth companies.
ECNS — Live Price Chart
Real-time chart from TradingView.
ECNS ETF Vitals & Key Statistics
Core data as of May 2026.
| Data Point | Value | Data Point | Value |
|---|---|---|---|
| Full Name | iShares MSCI China Small-Cap ETF VanEck | Ticker | ECNS |
| Issuer | BlackRock (iShares) | Asset Class | Equity: China Small-Cap |
| Index Tracked | MSCI China Small Cap Index | Structure | Open-Ended Fund |
| Expense Ratio | 0.59% | AUM | ~$68M |
| Inception Date | September 28, 2010 | Exchange | AMEX |
| No. of Holdings | 275 | Dividend Yield | 5.63% |
| 52-Week High | $40.05 | 52-Week Low | $22.91 |
| Avg Daily Volume | 17,300–33,000 | YTD Return | 36.42% |
| 1-Year Return | 36.42% | 5-Year Return | 2.79% |
| Category | China Region / Small Cap | Dividend Frequency | Semi-Annual |
ECNS Top 10 Holdings (May 2026)
Largest positions by weight. Click columns to sort.
| Rank | Ticker | Company Name | Sector | Weight % |
|---|---|---|---|---|
| 1 | 2099.HK | China Gold International Resources | Non-Energy Minerals | 2.10% |
| 2 | 0425.HK | Minth Group Limited | Producer Manufacturing | 1.72% |
| 3 | ZLAB | Zai Lab Limited | Health Technology | 1.70% |
| 4 | 9995.HK | RemeGen Co. Ltd | Health Technology | 1.46% |
| 5 | 2400.HK | XD Inc. | Technology Services | 1.46% |
| 6 | 1258.HK | China Nonferrous Mining Corp | Non-Energy Minerals | 1.33% |
| 7 | 9880.HK | UBTECH Robotics Corp Ltd | Electronic Technology | 1.32% |
| 8 | 2259.HK | XtalPi Holdings Limited | Health Technology | 1.32% |
| 9 | 6855.HK | Ascentage Pharma Group | Health Technology | 1.29% |
| 10 | KC | Kingsoft Cloud Holdings | Technology Services | 1.18% |
ECNS — Pros & Cons
✓ Domestic Growth Focus
Captures the growth of smaller, private Chinese firms that are often more aligned with domestic consumption and innovation than state giants.
✗ Liquidity Risks
With an AUM of ~$68M and relatively low daily trading volume, large orders can experience significant slippage and wider bid-ask spreads.
✓ High Income Yield
A 5.63% dividend yield provides a strong cushion for total returns, which is exceptional for a small-cap international equity fund.
✗ Emerging Market Volatility
Chinese small caps are subject to intense regulatory shifts and geopolitical tensions that can lead to rapid, double-digit price declines.
✓ Portfolio Diversification
Low correlation to the U.S. market and even large-cap Chinese tech, making it an excellent diversifier for sophisticated portfolios.
✗ Sector Concentration
Heavily weighted toward Health Tech and Finance; downturns in these specific sectors will disproportionately impact the fund’s NAV.
Who Should Consider ECNS?
Aggressive investors seeking alpha through niche international markets and those wanting exposure to Chinese medical and robotics innovation.
Conservative investors, those near retirement, or anyone uncomfortable with the unique regulatory risks associated with Chinese equity markets.
You believe the Chinese domestic economy is bottoming out and you want to participate in a high-beta recovery play beyond the standard large-caps.
Tax-advantaged accounts like an IRA or 401(k) are preferable to house the 5.63% dividend yield and protect against high turnover taxes.
ECNS vs Similar ETFs
Key metrics comparison.
| ETF | Full Name | Expense Ratio | AUM | Holdings | Div Yield | YTD | Best For |
|---|---|---|---|---|---|---|---|
| ECNS ★ | iShares MSCI China Small-Cap ETF | 0.59% | ~$68M | 275 | 5.63% | 36.42% | Small-cap niche growth |
| MCHI | iShares MSCI China ETF | 0.59% | ~$6B | 587 | 2.50% | ~12% | Broad market coverage |
| FXI | iShares China Large-Cap ETF | 0.74% | ~$4B | 50 | 3.05% | ~15% | Liquid blue-chip stocks |
| LABU ★ | Direxion Daily Biotech Bull 3X | 0.95% | Various | N/A | 0.00% | Variable | Leveraged biotech plays |
ECNS Technical Analysis
Real-time buy/sell signals.
ECNS — Risks & Considerations
Geopolitical Friction
Ongoing trade tensions between China and the U.S. can lead to delisting threats or investment restrictions on specific Chinese small-cap names.
Small-Cap Fragility
Small companies in emerging markets often have less access to capital and are more likely to fail during severe economic contractions.
Currency Fluctuation
The fund is exposed to fluctuations in the Chinese Yuan (CNY) and Hong Kong Dollar (HKD) against the U.S. Dollar.
Regulatory Overhaul
Sudden changes in Chinese government policy regarding private education, tech, or healthcare can wipe out sector gains overnight.